Earnings Estimates Rising for CorMedix (CRMD): Will It Gain?

Core Insights - CorMedix (CRMD) is experiencing solid improvement in earnings estimates, which may lead to continued short-term price momentum [1][2] - The rising trend in estimate revisions reflects growing analyst optimism regarding the company's earnings prospects, which is expected to positively impact its stock price [2][3] Current-Quarter Estimate Revisions - For the current quarter, CorMedix is expected to earn $0.48 per share, representing a significant increase of +1,060.0% from the previous year [6] - The Zacks Consensus Estimate for CorMedix has risen by 55.1% over the last 30 days, with three estimates moving higher and no negative revisions [6] Current-Year Estimate Revisions - For the full year, the expected earnings per share for CorMedix is $1.85, indicating a year-over-year change of +716.7% [7] - The consensus estimate has increased by 77.35% during this time frame, with three estimates moving higher and no negative revisions [7][8] Zacks Rank and Performance - CorMedix has achieved a Zacks Rank 2 (Buy) due to favorable estimate revisions, which is a strong indicator for potential investment [9] - Stocks with Zacks Rank 1 (Strong Buy) and 2 (Buy) have historically outperformed the S&P 500 [9] Bottom Line - Strong estimate revisions have led to a 7.9% increase in CorMedix's stock over the past four weeks, suggesting further upside potential [10]